Volume | 128,532 |
|
|||||
News | - | ||||||
Day High | 2.58 | Low High |
|||||
Day Low | 2.32 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Galectin Therapeutics Inc | GALT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.58 | 2.32 | 2.58 | 2.33 | 2.50 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,440 | 128,532 | $ 2.49 | $ 319,479 | - | 1.28 - 4.2684 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:48:17 | 10 | $ 2.33 | USD |
Galectin Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
144.11M | 61.85M | - | 0 | -44.81M | -0.72 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Galectin Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GALT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.70 | 2.7997 | 2.32 | 2.63 | 125,713 | -0.37 | -13.70% |
1 Month | 3.18 | 3.28 | 2.32 | 2.76 | 115,156 | -0.85 | -26.73% |
3 Months | 2.36 | 4.2684 | 2.26 | 3.31 | 195,562 | -0.03 | -1.27% |
6 Months | 1.61 | 4.2684 | 1.555 | 2.89 | 129,448 | 0.72 | 44.72% |
1 Year | 1.41 | 4.2684 | 1.28 | 2.53 | 95,235 | 0.92 | 65.25% |
3 Years | 3.30 | 4.40 | 1.02 | 3.02 | 281,945 | -0.97 | -29.39% |
5 Years | 3.89 | 5.70 | 1.02 | 3.00 | 391,595 | -1.56 | -40.10% |
Galectin Therapeutics Description
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis. |